Skip to Content
Merck
CN

B1532

Resorufin benzyl ether

CYP450 substrate, ≥98% (TLC), powder

Synonym(s):

7-Benzyloxy-3H-phenoxazin-3-one, 7-Benzyloxyresorufin, O7-Benzylresorufin

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H13NO3
CAS Number:
87687-02-3
Molecular Weight:
303.31
MDL number:
MFCD00171613
UNSPSC Code:
12352204
PubChem Substance ID:
24891597
NACRES:
NA.32

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Resorufin benzyl ether, CYP450 substrate

Quality Level

200

Assay

≥98% (TLC)

form

powder

solubility

chloroform: 9.80-10.20 mg/mL, clear, orange

storage temp.

2-8°C

SMILES string

O=C1C=CC2=Nc3ccc(OCc4ccccc4)cc3OC2=C1

InChI

1S/C19H13NO3/c21-14-6-8-16-18(10-14)23-19-11-15(7-9-17(19)20-16)22-12-13-4-2-1-3-5-13/h1-11H,12H2

InChI key

XNZRYTITWLGTJS-UHFFFAOYSA-N

General description

Fluorimetric substrate for cytochrome P450-linked enzymes.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000300650
0000300650
0000235437
0000229250
0000229250

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Seth Kwabena Amponsah et al.
Evidence-based complementary and alternative medicine : eCAM, 2020, 7956493-7956493 (2020-07-28)
There is considerable evidence that many patients concurrently administer dietary supplements with conventional drugs, creating a risk for potential drug-supplement interaction. The aim of this study was to determine the effect of Cellgevity® supplement on selected rat liver cytochrome P450
Lana X Garmire et al.
Pharmaceutical research, 24(12), 2171-2186 (2007-08-19)
Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions. We used the synthetic modeling method. Specialized software
Shosaku Kashiwada et al.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 141(4), 338-348 (2005-08-23)
Phylogenic analysis of the teleost genomic lineages has demonstrated the precedent for multiple genome duplications. Among many of the genes duplicated, cytochrome P450 genes have undergone independent diversification, which can be traced to a single ancestral gene. In teleosts, cytochrome
L E Beebe et al.
Biochemical pharmacology, 52(10), 1507-1513 (1996-11-22)
Suicide inhibitors of cytochrome P450 families are excellent tools to predict which isoforms mediate the metabolism/activation of a variety of chemical agents. We compared the inhibitory effects of several arylalkynes on mouse cytochromes P450 with published data for the rat
R Perrin et al.
Biochemical pharmacology, 40(9), 2145-2151 (1990-11-01)
The regional and subcellular distributions of rat brain cytochrome P450 and cytochrome P450-dependent activities were examined. Cytochrome P450 was found to be mainly localized in mitochondria in all the six cerebral regions studied. The activities of the isoforms mostly implicated
View All Related Papers

Articles

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

一期药物代谢

一期生物转化反应在药物上引入或暴露官能团，目的是增加化合物的极性。尽管一期药物代谢发生在大多数组织中，但代谢的主要和首过部位发生在肝循环期间。

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service